C反应蛋白联合肿瘤标志物在肺癌诊断中的应用价值

Application value of C-reactive protein and tumor markers in the diagnosis of lung cancer

目的探讨C反应蛋白(CRP)与肿瘤标志物检测在肺癌诊断中的价值。方法选取我院2015年2月至2017年5月收治的54例肺癌患者作为肺癌组,同时选取37例肺部良性病变患者为对照组。取患者外周血检测CRP、CEA、NSE、Cyfra21-1含量并进行组间比较。结果肺癌组患者的血清CRP、CEA、NSE、Cyfra21-1水平均显著高于对照组患者(P<0.05)。鳞癌患者血清CRP水平明显高于腺癌及小细胞肺癌患者(P<0.05)。ROC曲线及Logistic回归分析结果显示,单独应用CRP、CEA、NSE、Cyfra21-1诊断肺部良恶性疾病曲线下面积(AUC)分别为0.726、0.825、0.834、0.824,联合应用上述四项指标诊断肺部良恶性疾病AUC为0.961。结论肺癌患者的CRP出现升高,联合应用CRP及肿瘤标志物检测可以提高肺癌的检出率。

Objective To investigate the application value of C-reactive protein(CRP)and tumor markers in the diagnosis of lung cancer.Methods From February2015to May2017,54lung cancer patients admitted in our hospital were selected as lung cancer group,and37benign lung disease patients were enrolled as control group.The content of CRP,CEA,NSE and Cyfra21-1in the patients'peripheral blood were detected and compared between the two groups.Results The level of CRP,CEA,NSE and Cyfra21-1in the lung cancer group were higher than those in the control group(P<0.05).The CRP levels in the squamous cell carcinoma patients were higher than those in the adenocarcinoma and non-squamous carcinoma patients(P<0.05).The results of ROC curve and Logistic regression analysis showed that the AUC in separate detections of CRP,CEA,NSE and Cyfra21-1in the diagnosis of lung benign and malignant diseases were0.726,0.825,0.834and0.825,and that of the combination detection of four indicators in the diagnosis of benign and malignant pulmonary disease was0.961.Conclusion CRP increases in lung cancer patients,and CRP combined with tumor marker detection can improve the detection rate of lung cancer.